Compass Therapeutics (CMPX) Operating Expenses (2018 - 2026)

Compass Therapeutics has disclosed Operating Expenses across 9 years of filings, most recently posting $20.3 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $20.3 million, up 12.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $75.2 million (up 19.94% YoY), and the FY2025 annual result was $72.8 million, up 26.73% from the prior year.
• Operating Expenses came in at $20.3 million for Q1 2026 at Compass Therapeutics, up from $18.0 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $21.1 million in Q2 2025 to a low of $7.2 million in Q1 2022.
• The 5-year median for Operating Expenses is $13.3 million (2023), against an average of $14.3 million.
• Across the five-year window, Operating Expenses soared 115.2% in 2022 and dropped 5.33% in 2023, its largest moves.
• Compass Therapeutics' Operating Expenses stood at $12.9 million in 2022, then climbed by 19.44% to $15.4 million in 2023, then gained by 7.67% to $16.6 million in 2024, then increased by 8.54% to $18.0 million in 2025, then advanced by 12.83% to $20.3 million in 2026.
• The last three Operating Expenses figures came in at $20.3 million (Q1 2026), $18.0 million (Q4 2025), and $15.8 million (Q3 2025), per Business Quant data.